Delta-8-THC shows liver protection in a mouse hepatitis model
Delta-8-tetrahydrocannabinol ameliorates murine autoimmune hepatitis and is associated with epigenetic modulation of immune responses.
AI Summary
This abstract-based study asked whether delta-8-tetrahydrocannabinol (Δ8-THC) could protect the liver and regulate immunity in a mouse model of autoimmune hepatitis. Female mice were given concanavalin A to induce liver inflammation and then treated with 20 mg/kg Δ8-THC; researchers examined liver immune cells, microRNAs, gene activity, and CD4+ T-cell behavior. This was an animal and laboratory study, not a human clinical trial.
In the model, Δ8-THC suppressed the induced autoimmune hepatitis and shifted liver immunity away from inflammatory cells and toward a more tolerogenic state. It reduced inflammatory monocytes, neutrophils, natural killer cells, and inflammatory CD4+ T-cell responses, while preserving tolerogenic Kupffer cells and promoting regulatory T-cell expansion. The researchers linked these effects to preservation of miR-100-5p and miR-199a-3p, which were associated with lower mTOR expression and changes in T-cell differentiation. The abstract does not report quantitative effect sizes or clinical outcomes. Because the work was conducted in mice and cell models, it cannot establish that Δ8-THC treats autoimmune hepatitis in people; this is an abstract-based summary, not a full-text review.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More THC research papers you might find interesting.
Small lab study finds cannabis affected simulated driving and confidence
A lab method measures 17 cannabinoids across five hemp product types
A single-center study finds varied care and no recurrence in follow-up
Explore More Research
Stay informed about the latest cannabis science.